The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Relevance of Half-Life in Drug Design: Miniperspective
Abstract
Drug half-life has important implications for dosing regimen and peak-to-trough ratio at the steady state. A half-life of 12-48 h is generally ideal for once daily dosing of oral drugs. If the half-life is too short, it may require more frequent dosing in order to maintain desired exposures and avoid unnecessarily high peak concentrations. This may pose challenges to achieving optimal efficacy, safety, and patient compliance. If the half-life is too long, the time over which accumulation and subsequent elimination occur may be prolonged. This may pose problems with managing adverse effects and the design of efficient clinical trials. Half-life is a key parameter for optimization in research and development. Structural modification to affect clearance, and to a lesser extent volume of distribution, is the preferred means of modulating half-life. An effective approach to half-life optimization requires an understanding of the many pitfalls associated with its estimation and interpretation.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Disposition and Metabolism of Benoxaprofen in Laboratory Animals and Man
Chatfield, D. H., & Green, J. N. (1978) · Xenobiotica · doi:10.3109/00498257809060392 · Cited by 52
Research works printed but not linked: 31
- 10.1021/acs.jmedchem.5b00201 · doi:10.1021/acs.jmedchem.5b00201
- 10.1038/2071301a0 · DOI
- 10.1016/8756-3282(95)00445-9 · DOI · Paper page
- 10.1007/s40262-013-0071-8 · DOI
- 10.1124/dmd.115.067736 · DOI
- 10.1016/0002-8703(83)90006-6 · DOI · Paper page
- Plomp T. A., 1984, Arzneim. Forsch., 34, 513
- Anastasiou-Nana M., 1982, Int. J. Clin. Pharmacol. Ther. Toxicol., 20, 524
- 10.2165/00003088-198409020-00002 · DOI · Paper page
- Kannan R., 1985, Drug Metab. Dispos., 13, 646
- 10.1038/nrd3287 · DOI · Paper page
- 10.1021/jm5007935 · DOI
- Ding H., 2016, Applied Biopharmaceutics and Pharmacokinetics, 567
- Ummadi S., 2013, International Journal of Pharma Sciences, 3, 258
- 10.18433/J38W25 · DOI
- 10.5402/2012/528079 · DOI
- 10.1111/j.1365-2125.1986.tb02874.x · DOI · Paper page
- 10.2165/00003088-198815010-00001 · doi:10.2165/00003088-198815010-00001
- 10.1002/bdd.2510070102 · doi:10.1002/bdd.2510070102
- 10.1124/dmd.108.020479 · DOI · Paper page
- 10.2165/00003088-199630010-00003 · DOI
- 10.1002/jcph.734 · DOI
- 10.1002/cpt.576 · DOI
- 10.2174/1389200033489253 · DOI · Paper page
- 10.1111/j.1365-2125.1984.tb02362.x · DOI
- 10.1007/s11095-008-9787-9 · DOI · Paper page
- 10.1002/j.1552-4604.1995.tb04117.x · DOI · Paper page
- 10.1080/004982500406453 · doi:10.1080/004982500406453
- Nash J. F., 1980, J. Rheumatol., Suppl., 6, 12
- 10.1136/bmj.284.6326.1365 · doi:10.1136/bmj.284.6326.1365
- Hamdy R. C., 1982, Eur. J. Rheumatol. Inflammation, 5, 69
Cited by
“Magic Chloro”: Profound Effects of the Chlorine Atom in Drug Discovery
Chiodi, D., & Ishihara, Y. (2023) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.2c02015 · Cited by 263
Rosato, I., Bonato, T., Fletcher, T., Batzella, E., & Canova, C. (2024) · Environmental Research · doi:10.1016/j.envres.2023.117743 · Cited by 273
Metadata
- Authors
- Smith, D. A., Beaumont, K., Maurer, T. S., & Di, L.
- Venue
- Journal of Medicinal Chemistry
- Publisher
- American Chemical Society (ACS)
- Published
- 2017-11-07
- Volume
- 61
- Issue
- 10
- Pages
- 4273-4282
- ISSN
- 0022-2623 (ISSN-L)
- 1520-4804
- OpenAlex
- W2767714545
- Cited by
- 199
- References
- 1
- FWCI
- 8.38
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Relevance of Half-Life in Drug Design: Miniperspective. https://app.cochat.ai/papers/10.1021/acs.jmedchem.7b00969
- The paper
- Smith, D. A., Beaumont, K., Maurer, T. S., & Di, L. (2018). Relevance of Half-Life in Drug Design: Miniperspective. Journal of Medicinal Chemistry. https://doi.org/10.1021/acs.jmedchem.7b00969
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.